Cell Therapy News Volume 21.31 | Aug 31 2020

    By
    Justin.choi
    -
    0
    31







    CTN 21.31 | Aug 31


    Cell Therapy News by STEMCELL Technologies
    Vol. 12.31 – 31 August, 2020
    TOP STORY

    Single-Cell Transcriptome Profiling Reveals β Cell Maturation in Stem Cell-Derived Islets after Transplantation

    The authors provided a comprehensive resource for understanding human islet cell maturation and provided important insights into maturation of human pluripotent stem cells differentiated to insulin-secreting β cells (SC-β cells) and other SC-islet cell types to enable future differentiation strategy improvements.
    [Cell Reports]

    Full ArticleGraphical Abstract


    Watch this lively panel discussion about hPSC lines for cell therapies at the Nature Research Round Table on hPSC Quality
    PUBLICATIONSRanked by the impact factor of the journal

    Human Umbilical Cord-Derived Mesenchymal Stem Cell Therapy in Patients with COVID-19: A Phase I Clinical Trial

    Investigators performed a controlled, non-randomized, Phase I clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease.
    [Signal Transduction and Targeted Therapy]

    Full Article

    Aligned Collagen Scaffold Combination with Human Spinal Cord-Derived Neural Stem Cells to Improve Spinal Cord Injury Repair

    Researchers transplanted human fetal brain- or spinal cord- derived neural stem/progenitor cells into rats with complete transection spinal cord injury (SCI) to monitor their differences in SCI treatment.
    [Biomaterials Science]

    Abstract

    Posterior Reversible Encephalopathy Syndrome after Allogeneic Stem Cell Transplantation in Pediatric Patients with Fanconi Anemia, a Prospective Study

    Scientists evaluated incidence, clinical, and imaging features of posterior reversible encephalopathy syndrome in pediatric patients with FA following hematopoietic stem cell transplantation.
    [Biology of Blood and Marrow Transplantation]

    Abstract

    Donor Myeloid Derived Suppressor Cells (MDSCs) Prolong Allogeneic Cardiac Graft Survival through Programming of Recipient Myeloid Cells In Vivo

    As myeloid-derived suppressor cells (MDSCs) are potent immunoregulatory cells, investigators tested whether donor-derived MDSCs could protect heart transplant allografts in an antigen-specific manner.
    [Scientific Reports]

    Full Article

    A Highly Efficient Non-Viral Process for Programming Mesenchymal Stem Cells for Gene Directed Enzyme Prodrug Cancer Therapy

    Scientists showed the high transfection efficiency of human adipose tissue derived-MSCs using a cost-effective and off-the-shelf Polyethylenimine, in the presence of histone deacetylase 6 inhibitor and fusogenic lipids.
    [Scientific Reports]

    Full Article

    Direct Comparison of Therapeutic Effects on Diabetic Polyneuropathy between Transplantation of Dental Pulp Stem Cells and Administration of Dental Pulp Stem Cell-Secreted Factors

    Researchers directly compared the efficacy of the transplantation of dental pulp stem cells (DPSCs) and the administration of the secreted factors from DPSCs on diabetic polyneuropathy.
    [International Journal of Molecular Sciences]

    Full Article

    Pancreas-Derived Mesenchymal Stromal Cells Share Immune Response-Modulating and Angiogenic Potential with Bone Marrow Mesenchymal Stromal Cells and Can Be Grown to Therapeutic Scale Under Good Manufacturing Practice Conditions

    MSC isolates were derived from low-purity islet fractions and expanded in platelet lysate-supplemented medium or in commercially available xenogeneic-free medium.
    [Cytotherapy]

    Full Article

    Long-Term Follow-Up of CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

    The authors focused on the survival of 35 patients with B-cell acute lymphoblastic leukemia who relapsed after allo-hematopoietic stem cell transplantation and received CAR T cells.
    [Cytotherapy]

    Abstract

    Apply to be a host on the Immunology Podcast.
    REVIEWS

    Gene Delivery to the Skin – How Far Have We Come?

    Investigators discuss current approaches, successes, and failures of cutaneous gene therapy and provide guidance toward the development of next-generation concepts in gene therapy.
    [Trends in Biotechnology]

    Full Article

    Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies

    A recent study reported on the use of chimeric antigen receptor (CAR) T cell therapy as a novel senolytic approach and demonstrated improved cancer outcome and reversal of senescence-associated pathologies in animal models. Scientists aim to discuss the opportunities and limitations of translating such a therapeutic strategy into the clinic.
    [Molecular Therapy]

    Abstract

    Multifaceted Behavior of PEST Sequence Enriched Nuclear Proteins in Cancer Biology and Role in Gene Therapy

    The authors highlight the multifaceted behavior of proline, glutamic acid, serine, and threonine nuclear proteins (PEST-NPs) in cancer biology. They summarize a number of studies to address the influence of structure and PEST‐mediated posttranslational modifications on activation, localization, stability, and protein–protein interactions of PEST‐NPs.
    [Journal of Cellular Physiology]

    Abstract

    INDUSTRY AND POLICY NEWS

    Alberta Becomes 3rd Province to Offer Promising Leukemia and Lymphoma Treatment

    The Province of Alberta and the Alberta Cancer Foundation said that they were teaming up to invest $15 million to offer the leading edge therapy that sees a patient’s own immune cells genetically reprogrammed to attack cancer cells in their body.
    [CBC]

    Press Release

    NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

    NantKwest, Inc. announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic. The two product candidates currently in development under the agreement are a mesenchymal stem cell therapeutic from NantKwest, whose goal is to reduce the time a critically ill patient spends on a ventilator; and a COVID-19 vaccine product from ImmunityBio, which is anticipated to soon enter into a Phase I clinical trial.
    [NantKwest, Inc. ]

    Press Release

    FEATURED EVENT

    CAR-T Beyond Oncology Digital Event

    November 18, 2020
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Research Officer – T Cell Signaling Pathways

    National Research Council – Ottowa, Ontario, Canada

    Postdoctoral Scholar – Biomedical Engineering in Regenerative Medicine

    Pennsylvania State University – Philadelphia, Pennsylvania, United States

    Postdoctoral Fellow – Immunotherapy

    Roswell Park Center for Immunotherapy – Buffalo, New York, United States

    Research Fellow – Multiple Myeloma

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Research Fellow – Neural Cell Therapy

    Nanyang Technological University – Singapore, Singapore

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cell Therapy News Archives Contact Us
    Cell Therapy News Twitter